DEA Approval Necessary to Act on Recent Amendments to Illinois Law Granting APNs and PAs the Authority to Prescribe Schedule II Controlled Substances
Healthcare Alert | 1 min read
Feb 5, 2010
In August 2009, three Illinois Acts were amended, granting Advanced Practice Nurses (APNs) and Physician Assistants (PAs) the authority to prescribe Schedule II controlled substances. The Illinois Nurse Practice Act, Physician Assistant Act and Controlled Substances Act that had previously authorized the delegation of prescriptive authority (pursuant to a written collaborative or supervision agreement) only in regard to Schedule III-V controlled substances, now permit the delegation of such authority for Schedule II substances. Despite the state law amendments, however, APNs and PAs practicing in Illinois must await formal DEA approval before registering for updated state and federal controlled substances registration.
Under the amended Acts, APNs and PAs will have limited prescriptive authority. Specifically, APNs and PAs may be delegated no more than five Schedule II controlled substances by oral dosage and all prescriptions must be limited to no more than a 30-day oral dosage. In addition, only those controlled substances that the collaborating or supervising physician prescribes may be delegated, and the APN or PA must meet with the collaborating or supervising physician monthly to discuss the condition of those patients for whom a controlled substance is prescribed.
DEA approval is expected later this year. Upon approval, the Illinois Department of Financial and Professional Regulation will release updated forms and applications for revised controlled substances registration. After acquiring proper state registration, APNs and PAs will be required to apply for a revised or updated DEA number. Both must be obtained prior to acting upon the delegation of authority permitted under the recent statutory amendments.
For more information, please contact Stephen T. Moore or your regular Hinshaw attorney.
This alert has been prepared by Hinshaw & Culbertson LLP to provide information on recent legal developments of interest to our readers. It is not intended to provide legal advice for a specific situation or to create an attorney-client relationship.
Related People
Related Capabilities
Featured Insights

Employment Law Observer
Aug 10, 2026
As Leaves Fall, Leave Requests Rise: Are You Compliant With Chicago’s Expanded Rules?

Press Release
Aug 7, 2026
Daniel McGrath Re-Elected Senior Director of the Federation of Defense & Corporate Counsel

Insights for Insurers Alert
Aug 7, 2026
California Supreme Court Clarifies Pleading Standards for Excess Policy Claims

Press Release
Aug 6, 2026
Charles Townsend Named a Best Mentor Finalist in the 2026 ALM Texas Legal Awards

Webinar
Aug 5, 2026
April Toy Moderates HNBA Webinar on AI in the Practice of Law

Privacy, Cyber & AI Decoded Alert
Aug 5, 2026
2026 AI Compliance: Upcoming Laws Every Organization Needs to Know

Press Release
July 21, 2026 | Updated on August 4, 2026
Three Hinshaw Attorneys Named to the 2026 National Black Lawyers’ Top 40 Under 40 List

Healthcare Alert
Aug 3, 2026
Fixing the Emergency Refill Trap: What California’s AB 1587 Means for Pharmacies

Consumer Crossroads: Where Financial Services and Litigation Intersect
Jul 30, 2026
Should Text Messages be Considered “Calls” Under the TCPA? The Seventh Circuit Says No

Healthcare Alert
Jul 30, 2026
California Courts Sharply Curtail the MICRA Damages Cap in Nursing Home Litigation

Insights for Insurers Alert
Jul 30, 2026
Analyzing a Couple of Cases Involving Exclusions in D&O Policies


